Drug Profile
NX 001
Alternative Names: NX001Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NephRx Corporation
- Class Growth factors; Peptides
- Mechanism of Action Growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Delayed graft function
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Delayed-graft-function(Prevention, In volunteers) in USA
- 11 Nov 2010 NephRx Corporation receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA)
- 11 Nov 2010 Phase-I clinical trials in Delayed graft function in USA (unspecified route)